



ARDIAN

1810A Embarcadero Road
Palo Alto, California 94303
www.ardian.com
e-mail: info@ardianinc.com

For More Information:

Gregory Bakan
VP Sales & Marketing
Phone: 650.496.5555
Fax: 650.496.5556

About Ardian

Ardian, Inc., headquartered in Palo Alto, California, is a pioneering private, clinical-stage medical device company developing a novel catheter-based treatment for hypertension, chronic kidney disease and heart failure; these three interdependent disease states represent a significant, escalating global health problem. Ardian is the eighth company created by The Foundry, a leading medical device incubator based in Menlo Park, California.

Hypertension – Unmet Clinical Need

- Affects one billion people - 1 in every 3 adults in the developed world
- Single most common contributor to death worldwide
- Significantly increases the risk of heart attack, stroke, heart failure and chronic kidney disease
- Approximately 62% of cerebrovascular disease and 49% of ischemic heart disease are attributable to suboptimal control of blood pressure, according to the World Health Organization
- Consequences of uncontrolled hypertension are deadly: every 20 mmHg increase in systolic blood pressure correlates with a doubling of cardiovascular mortality
- A major public health burden: US\$ 73 billion/year, 45 million office visits

Hypertension – Market Opportunity

- Over US\$ 30 billion market worldwide for hypertension drugs
- Only 35% of hypertensive patients are satisfactorily controlled with existing medication - few alternatives for uncontrolled hypertension exist
- An increasing number of patients are becoming resistant to medical therapy, only one half of those treated are adequately controlled with medications

Sympathetic Modulation – A Time-tested Approach

- Chronic activation of the sympathetic nervous system (SNS) is a known culprit in hypertension, heart failure and chronic kidney disease
- Common anti-hypertension agents (ACE Inhibitors, Diuretics, ARB's, Beta Blockers, Calcium Channel Blockers, etc.) have long targeted portions of the SNS, particularly the kidney and its hormones
- Disrupting the nerves between the kidneys and the brain has been shown to inhibit SNS activity directly
- Over 70 years of surgical sympathetic modulation procedures, along with kidney transplant experience, have demonstrated potential for blood pressure control without impairing kidney function

The Symplicity® Catheter System™

- The Symplicity® Catheter System uses a minimally invasive approach to sympathetic nervous system modulation by delivering radiofrequency (RF) energy through a catheter
- The treatment is a straightforward, 40-minute catheterization laboratory procedure
- The System consists of two main components (the Symplicity® Catheter and the Symplicity® Generator), designed to work together to ensure consistent performance
- This System offers several advantages
 - Early safety, efficacy and durability data are promising
 - No permanent implant
 - Catheter is compatible with existing interventional technique
 - Potential for one-time treatment
 - Automated, pedal-activated Generator operation
 - Built-in control mechanisms to ensure safety

Milestones

- The Symplicity® Catheter System has been studied in clinical trials in Australia, Europe and the US
- Early clinical data were presented in 2008 at the European Society of Cardiology and at the Transcatheter Cardiovascular Therapeutics Conferences
- Further data, presented on March 30, 2009 at the American College of Cardiology Meeting and simultaneously published in *The Lancet*®, showed significant, safe and durable blood pressure reductions of -21/-10, -22/-11, -24/-11, and -27/-17 mmHg at 3, 6, 9, and 12 months respectively with no evidence of vascular abnormality (e.g., stenosis) or impairment of kidney function
- Completed \$47 million financing led by Medtronic, March 2009
- The Symplicity® Catheter System is CE Marked; in the US, it is under investigational use only

Board of Directors

- Allan Will (Split Rock Partners)
- Andrew Cleeland (Ardian)
- Hank Plain (Morgenthaler Ventures)
- Hanson Gifford - Chairman (Foundry)
- Richard Kuntz, MD (Medtronic)
- Richard Popp, MD (Advanced Technology Ventures)

Management

- Andrew Cleeland – President & CEO
- Craig Straley – Vice President Clinical Affairs
- Denise Zarins – Vice President R&D (Co-Founder)
- Gregory Bakan – Vice President Sales & Marketing
- Paul Sobotka, MD – Chief Medical Officer
- Scott Wilson, PhD – Vice President QA/RA
- Tim Kahlenberg – Chief Financial Officer

Investors

- Morgenthaler Ventures
- Advanced Technology Ventures
- Split Rock Partners
- Medtronic Corporation
- Emergent Medical Partners